First Time Loading...

Suven Pharmaceuticals Ltd
NSE:SUVENPHAR

Watchlist Manager
Suven Pharmaceuticals Ltd Logo
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Watchlist
Price: 643.9 INR -0.27% Market Closed
Updated: May 12, 2024
Section:
 

Relative Value

The Relative Value of one SUVENPHAR stock under the Base Case scenario is 450.3 INR. Compared to the current market price of 643.9 INR, Suven Pharmaceuticals Ltd is Overvalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SUVENPHAR Relative Value
Base Case
450.3 INR
Overvaluation 30%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

14
P/S
P/S
Price to Sales
14
vs History
9
vs Industry
12
Median 3Y
11.1
Median 5Y
10.8
Industry
2.5
Forward
15
More Details
44.2
P/E
P/E
Price to Earnings
44.2
vs History
9
vs Industry
10
Median 3Y
32.4
Median 5Y
31.7
Industry
23.4
Forward
49.8
More Details
38
P/OCF
P/OCF
Price to OCF
38
vs History
11
vs Industry
12
Median 3Y
24
Median 5Y
0
Industry
17.9
More Details
61.2
P/FCFE
P/FCFE
Price to FCFE
61.2
vs History
23
vs Industry
10
Median 3Y
53.3
Median 5Y
0
Industry
24.1
More Details
8.5
P/B
P/B
Price to Book Value
8.5
vs History
38
vs Industry
7
Median 3Y
8.7
Median 5Y
8
Industry
2.1
More Details
13.4
EV/S
EV/S
Enterprise Value to Sales
13.4
vs History
9
vs Industry
11
Median 3Y
10.7
Median 5Y
10.5
Industry
2.6
Forward
14.4
More Details
22.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
22.9
vs History
9
vs Industry
9
Median 3Y
19.2
Median 5Y
18.2
Industry
5.2
More Details
31.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
31.5
vs History
13
vs Industry
11
Median 3Y
26.8
Median 5Y
24.7
Industry
13.9
Forward
35.9
More Details
34.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
34.8
vs History
9
vs Industry
12
Median 3Y
26.8
Median 5Y
25.8
Industry
17.5
Forward
37.4
More Details
36.3
EV/OCF
EV/OCF
Enterprise Value to OCF
36.3
vs History
11
vs Industry
12
Median 3Y
23.2
Median 5Y
0
Industry
16.4
More Details
50.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
50.1
vs History
23
vs Industry
10
Median 3Y
43.4
Median 5Y
0
Industry
18.1
More Details
11.5
EV/IC
EV/IC
Enterprise Value to IC
11.5
vs History
15
vs Industry
10
Median 3Y
10
Median 5Y
9.3
Industry
1.9
More Details

Multiples Across Competitors

SUVENPHAR Competitors Multiples
Suven Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
163.9B INR 14 44.2 31.5 34.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
722.3B USD 20.1 117.7 57.6 65.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.8B USD 4.2 9.4 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
329.4B USD 5.4 142.8 35.6 58.1
UK
AstraZeneca PLC
LSE:AZN
191.8B GBP 5 37.9 174.6 278.6
CH
Novartis AG
SIX:NOVN
180.6B CHF 3.4 11.4 8.7 12.6
CH
Roche Holding AG
SIX:ROG
179.5B CHF 3.1 15.6 8.9 10.5
US
Pfizer Inc
NYSE:PFE
158.1B USD 2.9 -511.8 12.7 20.2
P/E Multiple
Earnings Growth
IN
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Average P/E: 52.9
44.2
24%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
117.7
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
142.8
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.9
168%
CH
Novartis AG
SIX:NOVN
11.4
15%
CH
Roche Holding AG
SIX:ROG
15.6
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -511.8
680%

See Also

Summary
SUVENPHAR intrinsic value, competitors valuation, and company profile.
DCF Valuation
SUVENPHAR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SUVENPHAR stock valuation using valuation multiples.
Wall Street Estimates
SUVENPHAR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SUVENPHAR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.